GlaxoSmithKline's flu vaccine Arepanrix approved In Japan

TOKYO — GlaxoSmithKline PLC's Japanese unit said Jan. 20 that it has received approval from the Japanese government for its influenza vaccine Arepanrix H1N1.

GSK already has an agreement with the Japanese government to supply 74 million doses of Arepanrix H1N1, which is the first imported vaccine approved in Japan to cope with the swine flu outbreak.

In December, GlaxoSmithKline announced that the World Health Organization awarded prequalification for global use of Arepanrix, its adjuvanted H1N1 pandemic vaccine manufactured in Canada.